In opening its new translational research lab, Mass General claims to be "the first and only cancer center" to attempt to molecularly profile all cancer patients that present to the facility.
Chronix Biomedical, Rosetta Genomics, National Institute of General Medical Sciences, National Center for Genome Resources, Beyond Batten Disease Research Foundation, and more ...
During the firm's earnings call last week, CEO Amit Kumar said that the company's diagnostics services performance would be most indicative of how CombiMatrix would perform going forward.
The firm published data from a study showing that the same biomarker used in its miRNA-based test for squamous lung cancer provided 96 percent sensitivity.
In its annual report, Exiqon also indicated that it would eventually seek US Food and Drug Administration approval for its miRNA diagnostics so that they could be made available to a broader range of laboratories and pathologists.
In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.
